Sana Biotechnology, Inc. (SANA)

NMS – Real Time Price. Currency in USD

3.20

-0.06 (-1.84%)

At close: May 13, 2026, 4:00 PM EDT

3.15

-0.05 (-1.55%)

After-hours: May 13, 2026, 7:02 PM EDT

11.05.2026

Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates

Announced strategic collaboration with Mayo Clinic, focused on improving care in type 1 diabetes and accelerating development of SC451

05.05.2026

Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference

SEATTLE, May 05, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the BofA Securities 2026 Healthcare Conference at 2:20 p.m. PT on Tuesday, May 12, 2026.

27.04.2026

Sana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting

SEATTLE, April 27, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that an abstract highlighting preclinical data from SG293, its CD19-directed in vivo CAR T product candidate, has been accepted for oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting taking place May 11-15, 2026 in Boston, MA.

18.03.2026

Sana Biotechnology, Inc. (SANA) Presents at The Citizens Life Sciences Conference 2026 Transcript

06.03.2026

Sana Biotechnology, Inc. (SANA) Presents at TD Cowen 46th Annual Health Care Conference Transcript

03.03.2026

Sana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

Shared 12-month clinical results of ongoing UP421 type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression are safe and well-tolerated, evade detection by the immune system, and continue to function one year post-transplant

23.02.2026

Sana Biotechnology to Present at March 2026 Investor Conferences

SEATTLE, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in March. The presentations will feature a business overview and update.

Videos

No Data

There is no data to display

Press releases

11.05.2026

Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates

Announced strategic collaboration with Mayo Clinic, focused on improving care in type 1 diabetes and accelerating development of SC451

27.04.2026

Sana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting

03.03.2026

Sana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

08.12.2025

Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform

Data Demonstrate Potent in vivo Gene Editing of Hematopoietic Stem Cells (HSCs) in the Bone Marrow with Systemic Delivery in Preclinical Murine Models Using Fusogen Technology

Sana Biotechnology, Inc. (SANA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Sana Biotechnology, Inc. (SANA)

Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates

Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference

Sana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting

Sana Biotechnology, Inc. (SANA) Presents at The Citizens Life Sciences Conference 2026 Transcript

Sana Biotechnology, Inc. (SANA) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Sana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

Sana Biotechnology to Present at March 2026 Investor Conferences

Videos

No Data

Press releases

Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates

Sana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting

Sana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform

Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates

Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference

Sana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting

Sana Biotechnology, Inc. (SANA) Presents at The Citizens Life Sciences Conference 2026 Transcript

Sana Biotechnology, Inc. (SANA) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Sana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

Sana Biotechnology to Present at March 2026 Investor Conferences

Videos

No Data

Press releases

Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates

Sana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting

Sana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform

Search stocks

Sana Biotechnology, Inc. (SANA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Sana Biotechnology, Inc. (SANA)

Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates

Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference

Sana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting

Sana Biotechnology, Inc. (SANA) Presents at The Citizens Life Sciences Conference 2026 Transcript

Sana Biotechnology, Inc. (SANA) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Sana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

Sana Biotechnology to Present at March 2026 Investor Conferences

Videos

No Data

Press releases

Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates

Sana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting

Sana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform

Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates

Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference

Sana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting

Sana Biotechnology, Inc. (SANA) Presents at The Citizens Life Sciences Conference 2026 Transcript

Sana Biotechnology, Inc. (SANA) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Sana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

Sana Biotechnology to Present at March 2026 Investor Conferences

Videos

No Data

Press releases

Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates

Sana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting

Sana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform